Keensight Capital to acquire a majority stake in Isto Biologics from Thompson Street Capital Partners.

Keensight Capital, a private equity manager, agreed to acquire a majority stake in Isto Biologics, a medtech company developing and manufacturing orthobiologic products, from Thompson Street Capital Partners, a middle-market private equity firm. Financial terms were not disclosed. “We have been investors in the biomaterials, orthopedics, spine and bone repair segments for over 20 years, and have been tracking Isto specifically for more than 5 years. Isto is the perfect example of a Keensight healthcare investment: a company that offers proven technology which is improving patient lives, while delivering sustainable and profitable growth. We are very excited to support Isto with its continued domestic success and international expansion,” Amit Karna and David Piccoli, Keensight Capital Partners.